MediWound Ltd. (NASDAQ:MDWD) will hold its 3Q20 earnings conference call with the financial community on 10th November 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at www.mediwound.com
Earnings Expectation
MediWound Ltd. is reporting third quarter financial results on Tuesday 10th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, MDWD is expected to report 3Q20 loss of $ 0.1 per share from revenue of $ 5.79 million.
For the full year, analysts anticipate top line of $ 20.02 million, while looking forward to loss of $ 0.4 per share bottom line.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in Europe and Israel through its commercial organization, and Argentina and South Korea through its distributors to burn specialists treating patients with severe burns in burn centers and hospitals burn units. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders.
